News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Betagenon AB: First Time In Man-AMPK Activator O304


3/10/2014 10:06:42 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

STOCKHOLM--(BUSINESS WIRE)--The epidemic increase in obesity has generated a concomitant increase in fatty liver, non-alcoholic steato-hepatitis (NASH) and type 2 diabetes (T2D). Physical inactivity and T2D in elderly are in turn strongly associated with peripheral arterial disease (PAD), caused by reduced blood flow to the legs. Several 100 millions of patients globally live with NASH, T2D or PAD. There are very limited therapeutic options for NASH and PAD, and few new innovative drugs to treat T2D and associated complications. Thus, these diseases represent a serious threat to health care systems globally.

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES